Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection

Journal of Clinical Virology

Volumn 59, Issue 4, 2014, Pages 246-249

  Kwon, Min Jung ^a   Roh, Kyoung Ho ^b   Park, Hyosoon ^a   Woo, Hee Yeon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seegene Institute of Life Sciences   (South Korea)

Author keywords

Anyplex II HPV28; Genotypes; HC2; Human papilloma virus

Indexed keywords

ADULT; AGED; ANYPLEX II HUMAN PAPILLOMAVIRUS TYPE 28 ASSAY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HUMAN; HYBRID CAPTURE 2 ASSAY; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; YOUNG ADULT;

ANYPLEX II HPV28; GENOTYPES; HC2; HUMAN PAPILLOMA VIRUS;

ADULT; AGED; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY; YOUNG ADULT;

EID: 84895920309     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.01.015     Document Type: Article

References (27)

1. Clifford G.M., Smith J.S., Aguado T., Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
2. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362:1871-1876.
3. Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005, 32(Suppl 1):S43-S51.
4. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
5. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
6. Chun J.Y. High multiplex molecular diagnostics. Shifting the diagnostics paradigm. Seegene Bull 2012, 1:1-4.
7. Lee D.H. TOCE: Innovative technology for high multiplex real-time PCR. Seegene Bull 2012, 1:5-10.
8. Sotlar K., Diemer D., Dethleffs A., Hack Y., Stubner A., Vollmer N., et al. Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol 2004, 42:3176-3184.
9. Fuessel Haws A.L., He Q., Rady P.L., Zhang L., Grady J., Hughes T.K., et al. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004, 122:87-93.
10. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlee F., Hildesheim A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357-361.
11. Park S., Kang Y., Kim D.G., Kim E.C., Park S.S., Seong M.W. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients. Diagn Microbiol Infect Dis 2013, 76(4):432-436.
12. Park Y., Lee E., Choi J., Jeong S., Kim H.S. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol 2012, 50:2359-2365.
13. Choi J., Park Y., Lee E.H., Kim S., Kim J.H., Kim H.S. Detection and genotyping of human papillomavirus by five assays according to cytologic results. J Virol Methods 2013, 187:79-84.
14. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012, 50:1867-1873.
15. Schmitz M., Scheungraber C., Herrmann J., Teller K., Gajda M., Runnebaum I.B., et al. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 2009, 44:302-307.
16. Carcopino X., Henry M., Mancini J., Giusiano S., Boubli L., Olive D., et al. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 2012, 84:306-313.
17. Wanram S., Limpaiboon T., Leelayuwat C., Yuenyao P., Guiney D.G., Lulitanond V., et al. The use of viral load as a surrogate marker in predicting disease progression for patients with early invasive cervical cancer with integrated human papillomavirus type 16. Am J Obstet Gynecol 2009, 201:79.e1-79.e7.
18. Antonsson A., Forslund O., Ekberg H., Sterner G., Hansson B.G. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000, 74:11636-11641.
19. Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8.
20. IARC Agents classified by the IARC monographs, vol. 1-109. Int Agency Res Cancer 2012, http://monographs.iarc.fr/ENG/Classification/index.php.
21. Meites E., Lin C., Unger E.R., Steinau M., Patel S., Markowitz L.E., et al. Can clinical tests help monitor human papillomavirus vaccine impact?. Int J Cancer 2013, 133(5):1101-1106.
22. Yoshikawa H., Ebihara K., Tanaka Y., Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013, 104:465-472.
23. Sherman M.E., Wang S.S., Wheeler C.M., Rich L., Gravitt P.E., Tarone R., et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003, 12:1038-1044.
24. Spinillo A., Dal Bello B., Gardella B., Roccio M., Dacco M.D., Silini E.M. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009, 113:115-119.
25. Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholder S., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000, 283:87-93.
26. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
27. Kinney W., Stoler M.H., Castle P.E. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010, 134:193-199.